

## Special Issue

# The Role of Gut Microbiota in Gastrointestinal Cancers: From Pathogenesis to Therapeutic Perspectives

### Message from the Guest Editor

This Special Issue will focus on the role of gut microbiota in gastrointestinal cancers: from pathogenesis to therapeutic perspectives, and old and new tools used to evaluate carcinogenesis in vitro and in vivo. We emphasize the relevance of driver microbiota which accelerate inflammation and carcinogenesis, such as *Fusobacterium* spp. and others. This Issue includes reviews, opinions, and short articles from experts in the field. Submissions will cover all type of microbiota including bacteria, fungi, viruses, and bacteriophages that influence carcinogenesis and molecular pathways/factors playing key roles in persistent inflammation, various mouse models, and valuable cell lines and primary organoids. We hope that this Special Issue will help improve our understanding of the role of gut microbiota in gastrointestinal cancers.

### Guest Editor

Dr. Ryota Niikura

Department of Gastroenterology, Graduate school of Medicine, The University of Tokyo, Tokyo, Japan

### Deadline for manuscript submissions

closed (31 July 2022)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/66361](https://mdpi.com/si/66361)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).